122
Participants
Start Date
April 30, 2014
Primary Completion Date
August 31, 2015
Study Completion Date
August 31, 2015
LDV/SOF
90/400 mg FDC tablet administered orally
SOF
400 mg tablet administered orally once daily
RBV
Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
New York
Rochester
Philadelphia
Washington D.C.
Atlanta
Minneapolis
San Francisco
Sacramento
San Diego
Boston
Boston
Newark
Chapel Hill
Lead Sponsor
Gilead Sciences
INDUSTRY